Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $225.00 short call and a strike $235.00 long call offers a potential 25% return on risk over the next 23 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $225.00 by expiration. The full premium credit of $2.00 would be kept by the premium seller. The risk of $8.00 would be incurred if the stock rose above the $235.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 35.92 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Amgen Wins Patent Case on Otezla® (apremilast)
Mon, 20 Sep 2021 23:02:00 +0000
Amgen today announced that the U.S. District Court for the District of New Jersey has upheld patents that protect Amgen's psoriasis therapy Otezla® (apremilast) in a patent infringement lawsuit against Sandoz Inc. (“Sandoz”) and Zydus Pharmaceuticals (USA), Inc. (“Zydus”). The asserted patents claim apremilast as a composition of matter (“COM”), methods of treating psoriasis with apremilast, and crystalline forms of apremilast. The court found infringement and upheld the validity of four patents
Why Mirati Therapeutics Is A Dangerous Rival To Amgen In Colon Cancer
Mon, 20 Sep 2021 20:09:56 +0000
Mirati could beat Amgen to market with a KRAS-blocking colon cancer drug, an analyst said Monday as MRTX stock popped.
Why Verastem Stock Spiked Today
Mon, 20 Sep 2021 19:49:20 +0000
A clinical collaboration with biotech titan Amgen briefly lit a fire underneath Verastem's shares today.
Mirati drug combination shrinks tumors in 39% of colon cancer patients in study
Sun, 19 Sep 2021 13:47:00 +0000
A combination of Mirati Therapeutics Inc's genetic mutation-targeting adagrasib and older cancer drug Erbitux shrank tumors in 39% of patients with advanced colorectal cancer treated in a small trial, the company said on Sunday. Chief Executive Officer Charles Baum told Reuters Mirati plans to meet with the U.S. Food and Drug Administration in October to discuss whether it can pursue accelerated approval based on the combination therapy data. Adagrasib targets a mutated form of a gene known as KRAS that occurs in around 13% of non-small cell lung cancers, 3% to 5% of colorectal cancers and up to 2% of other solid tumor cancers.
Boasting A 70% Return On Equity, Is Amgen Inc. (NASDAQ:AMGN) A Top Quality Stock?
Thu, 16 Sep 2021 12:17:00 +0000
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like…
Also on Market Tamer…
Follow Us on Facebook